Interferon-γ and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes

Journal of Infectious Diseases

Volumn 191, Issue 7, 2005, Pages 1180-1187

  Gil Lamaignere, Cristina ^a,c,d   Simitsopoulou, Maria ^a   Roilides, Emmanuel ^a,b   Maloukou, Avgi ^a   Winn, Richard M ^a,b   Walsh, Thomas J ^b,c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d MUSGROVE PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 8; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

ABSIDIA; ADULT; ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; NEUTROPHIL; PRIORITY JOURNAL; RESPIRATORY BURST; RHIZOPUS; RHIZOPUS MICROSPORUS; RHIZOPUS ORYZAE; ZYGOMYCETES;

ABSIDIA; ADULT; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYPHAE; INTERFERON TYPE II; INTERLEUKIN-8; NEUTROPHILS; RESPIRATORY BURST; RHIZOPUS; TUMOR NECROSIS FACTOR-ALPHA; ZYGOMYCOSIS;

EID: 15544377441     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/428503     Document Type: Article

References (58)

1. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13:236-301.
2. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am 2002; 16:895-914, vi.
3. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30:851-6.
4. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-17.
5. Chakrabarti A, Das A, Panda N, Das S, Gupta KL, Sakhuja V. Ten years' experience in zygomycosis at a tertiary care centre in India. J Infect 2001; 42:261-6.
6. Leleu X, Sendid B, Fruit J, et al. Combined anti-fungal therapy and surgical resection as treatment of pulmonary zygomycosis in allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 24:417-20.
7. Thami GP, Kaur S, Bawa AS, Chander J, Mohan H, Bedi MS. Postsurgical zygomycotic necrotizing subcutaneous infection caused by Absidia corymbifera. Clin Exp Dermatol 2003; 28:251-3.
8. Morales-Aguirre JJ, Aguero-Echeverria WM, Ornelas-Carsolio ME, Resendiz-Sanchez J, Gomez-Barreto D, Cashat-Cruz M. Successful treatment of a primary cutaneous zygomycosis caused by Absidia corymbifera in a premature newborn. Pediatr Infect Dis J 2004; 23:470-2.
9. Diamond RD, Krzesicki R, Epstein B, Jao W. Damage to hyphal forms of fungi by human leukocytes in vitro: a possible host defense mechanism in aspergillosis and mucormycosis. Am J Pathol 1978; 91:313-28.
10. Chinn RYW, Diamond RD. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun 1982; 38:1123-9.
11. Levitz SM, Diamond RD. A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT. J Infect Dis 1985; 152:938-45.
12. Diamond RD, Clark RA. Damage to Aspergillus fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative microbicidal products of human neutrophils in vitro. Infect Immun 1982; 38:487-95.
13. Diamond RD, Haudenschild CC, Erickson NF. Monocyte-mediated damage to Rhizopus oryzae hyphae in vitro. Infect Immun 1982; 38: 292-7.
14. Christin L, Diamond RD, Wang S, Meshulam T, Wysong DR. Mechanisms and target sites of damage in killing of Candida albicans hyphae by human polymorphonuclear neutrophils. J Infect Dis 1997; 176:1567-78.
15. Levy O. A neutrophil-derived anti-infective molecule: bactericidal/permeability-increasing protein. Antimicrob Agents Chemother 2000; 44: 2925-31.
16. Hancock RE, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother 1999; 43:1317-23.
17. Ganz T, Lehrer RI. Antimicrobial peptides of leukocytes. Curr Opin Hematol 1997; 4:53-8.
18. Roilides E, Lyman CA, Panagopoulou P, Chanock S. Immunomodulation of invasive fungal infections. Infect Dis Clin North Am 2003; 17:193-219.
19. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993; 61:1185-93.
20. Vora S, Chauhan S, Brummer E, Stevens DA. Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 1998; 42:2299-303.
21. Gaviria JM, van Burik JA, Dale DC, Root RK, Liles WC. Comparison of interferon-γ, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. J Infect Dis 1999; 179:1038-41.
22. Epling-Burnette PK, Zhong B, Bai F, et al. Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J Immunol 2001; 166:7486-95.
23. Dale DC, Liles WC, Llewellyn C, Price TH. Effects of granulocyte- macrophage colony-stimulating factor (GM-CSF) on neutrophil kinetics and function in normal human volunteers. Am J Hematol 1998; 57:7-15.
24. Fossati G, Mazzucchelli I, Gritti D, et al. In vitro effects of GM-CSF on mature peripheral blood neutrophils. Int J Mol Med 1998; 1:943-51.
25. Cohen DM, Bhalla SC, Anaissie EJ, Hester JP, Savary CA, Rex JH. Effects of in vitro and in vivo cytokine treatment, leucapheresis and irradiation on the function of human neutrophils: implications for white blood cell transfusion therapy. Clin Lab Haematol 1997; 19:39-47.
26. Gougerot-Pocidalo MA, El Benna J, Elbim C, Chollet-Martin S, Dang MC. Regulation of human neutrophil oxidative burst by pro- and antiinflammatory cytokines. J Soc Biol 2002; 196:37-46.
27. Mukaida N. Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol 2000; 72:391-8.
28. Kuthan H, Ullrich V, Estabrook RW. A quantitative test for superoxide radicals produced in biological systems. Biochem J 1982; 203:551-8.
29. Meshulam T, Levitz SM, Christin L, Diamond RD. A simplified new assay for assessment of fungal cell damage with the tetrazolium dye, (2,3)-bis-(2- methoxy-4-nitro-5-sulphenyl)-(2H)-tetrazolium-5-carboxanil ide (XTT). J Infect Dis 1995; 172:1153-6.
30. Liles WC, Huang JE, van Burik JA, Bowden RA, Dale DC. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis 1997; 175:1012-5.
31. Winn RM, Gil-Lamaignere C, Maloukou A, Roilides E. Interactions of human phagocytes with moulds Fusarium spp. and Verticillium nigrescens possessing different pathogenicity. Med Mycol 2003; 41:503-9.
32. Gil-Lamaignere C, Roilides E, Lyman CA, et al. Human phagocytic cell responses to Scedosporium (Pseudallescheria boydii): variable susceptibility to oxidative injury. Infect Immun 2003; 71:6472-8.
33. Roilides E, Lyman CA, Filioti J, et al. Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus. Antimicrob Agents Chemother 2002; 46:1974-6.
34. Kapp A, Zeck-Kapp G. Activation of the oxidative metabolism in human polymorphonuclear neutrophilic granulocytes: the role of immuno-modulating cytokines. J Invest Dermatol 1990; 95(Suppl 6):94S-9S.
35. Al-Shami A, Mahanna W, Naccache PH. Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils. Selective activation of Jak2, Stat3, and Stat5b. J Biol Chem 1998; 273:1058-63.
36. Richardson MD, Brownlie CE, Shankland GS. Enhanced phagocytosis and intracellular killing of Candida albicans by GM-CSF-activated human neutrophils. J Med Vet Mycol 1992; 30:433-41.
37. Kudeken N, Kawakami K, Saito A. Cytokine-induced fungicidal activity of human polymorphonuclear leukocytes against Penicillium marneffei. FEMS Immunol Med Microbiol 1999; 26:115-24.
38. Kurita N, Oarada M, Miyaji M, Ito E. Effect of cytokines on antifungal activity of human polymorphonuclear leucocytes against yeast cells of Paracoccidioides brasiliensis. Med Mycol 2000; 38:177-82.
39. Tanida T, Rao F, Hamada T, Ueta E, Osaki T. Lactoferrin peptide increases the survival of Candida albicans-inoculated mice by upregulating neutrophil and macrophage functions, especially in combination with amphotericin B and granulocyte-macrophage colony-stimulating factor. Infect Immun 2001; 69:3883-90.
40. Hill AD, Naama H, Shou J, Calvano SE, Daly JM. Antimicrobial effects of granulocyte-macrophage colony-stimulating factor in protein-energy malnutrition. Arch Surg 1995; 130:1273-7; discussion 1277-8.
41. Chaves MM, Silvestrini AA, Silva-Teixeira DN, Nogueira-Machado JA. Effect in vitro of gamma interferon and interleukin-10 on generation of oxidizing species by human granulocytes. Inflamm Res 1996; 45:313-5.
42. Berton G, Zeni L, Cassatella MA, Rossi F. Gamma interferon is able to enhance the oxidative metabolism of human neutrophils. Biochem Biophys Res Commun 1986; 138:1276-82.
43. Klein JB, Scherzer JA, McLeish KR. Interferon-gamma enhances superoxide production by HL-60 cells stimulated with multiple agonists. J Interferon Res 1991; 11:69-74.
44. Morrison CJ, Stevens DA. Enhanced killing of Blastomyccs dermatitidis by gamma interferon-activated murine peripheral blood polymorphonuclear neutrophils. Int J Immunopharmacol 1989; 11:855-62.
45. Roilides E, Holmes A, Blake C, Pizzo PA, Walsh TJ. Effects of granulocyte colony-stimulating factor and interferon-γ on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species. J Leukoc Biol 1995; 57:651-6.
46. Lyman CA, Garrett KF, Pizzo PA, Walsh TJ. Response of human polymorphonuclear leukocytes and monocytes to Trichosporon beigelii: host defense against an emerging opportunistic pathogen. J Infect Dis 1994; 170:1557-65.
47. Nagai H, Guo J, Choi H, Kurup V. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis 1995; 172:1554-60.
48. Clemons KV, Lutz JE, Stevens DA. Efficacy of interferon-γ and amphotericin B for the treatment of systemic murine histoplasmosis. Microbes Infect 2001; 3:3-10.
49. Lutz JE, Clemons KV, Stevens DA. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J Antimicrob Chemother 2000; 46:437-42.
50. Clemons KV, Stevens DA. Treatment of orogastrointestinal candidosis in SCID mice with fluconazole alone or in combination with recombinant granulocyte colony-stimulating factor or interferon-gamma. Med Mycol 2000; 38:213-9.
51. Woodman RC, Erickson RW, Rae J, Jaffe HS, Curnutte JT. Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease: evidence against enhanced neutrophil oxidase activity. Blood 1992; 79:1558-62.
52. Schiff DE, Rae J, Martin TR, Davis BH, Curnutte JT. Increased phagocyte FcγRI expression and improved Fcγ-receptor-mediated phagocytosis after in vivo recombinant human interferon-γ treatment of normal human subjects. Blood 1997; 90:3187-94.
53. Gil-Lamaignere C, Winn RM, Simitsopoulou M, Maloukou A, Walsh TJ, Roilides E. IFN-γ and GM-CSF augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: comparison with Aspergillus spp. Med Mycol, in press.
54. Winn RM, Gil-Lamaignere C, Roilides E, Simitsopoulou M, Maloukou A, Walsh TJ. Selective effects of interleukin-15 on antifungal activity and interleukin-8 release by polymorphonuclear leukocytes in response to hyphae of Aspergillus spp. J Infect Dis 2003; 188:585-90.
55. Fanger NA, Liu C, Guyre PM, et al. Activation of human T cells by major histocompatability complex class II expressing neutrophils: proliferation in the presence of superantigen, but not tetanus toxoid. Blood 1997; 89:4128-35.
56. Gosselin EJ, Wardwell K, Rigby WF, Guyre PM. Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor, IFN-γ, and IL-3. J Immunol 1993; 151:1482-90.
57. Lei L, Altstaedt J, von der Ohe M, Proft T, Gross U, Rink L. Induction of interleukin-8 in human neutrophils after MHC class II cross-linking with superantigens. J Leukoc Biol 2001; 70:80-6.
58. Radsak M, Iking-Konert C, Stegmaier S, Andrassy K, Hansch GM. Polymorphonuclear neutrophils as accessory cells for T-cell activation: major histocompatibility complex class II restricted antigen-dependent induction of T-cell proliferation. Immunology 2000; 101:521-30.